Cargando…
Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review
SIMPLE SUMMARY: HER2-positive breast cancer (BC) is associated with an aggressive clinicopathological nature and is known to have a poor prognosis. Their tumor proliferation features can lead to visceral metastasis disseminating to the brain, liver, lung, and bone. Delivering standard chemotherapy H...
Autores principales: | Giffoni de Mello Morais Mata, Danilo, Chehade, Rania, Hannouf, Malek B., Raphael, Jacques, Blanchette, Phillip, Al-Humiqani, Abdullah, Ray, Monali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486709/ https://www.ncbi.nlm.nih.gov/pubmed/37686612 http://dx.doi.org/10.3390/cancers15174336 |
Ejemplares similares
-
Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer—A Literature Review
por: Mata, Danilo Giffoni de Mello Morais, et al.
Publicado: (2022) -
Antibody–Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond—A 2023 Review
por: Xiao, Tian, et al.
Publicado: (2023) -
Four Cycles of Docetaxel-Cyclophosphamide versus Anthracycline-Taxane as Adjuvant Chemotherapy for HER2-Negative, Axillary Lymph Node Negative Breast Cancer: A Real-World Comparison of Alberta Patients Treated 2008–2012
por: Hannouf, Malek, et al.
Publicado: (2021) -
Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis
por: Stewart, Paul, et al.
Publicado: (2020) -
Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer
por: Hannouf, Malek B, et al.
Publicado: (2012)